Phase I trials of pemetrexed

Seminars in Oncology

Volumn 29, Issue 2 SUPPL. 5, 2002, Pages 8-16

  Fossella, Frank V ^a,b   Gatzemeier, Ulrich ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; HUMAN; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 0036261539     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70210-8     Document Type: Review

References (19)

1. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents
2. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis
3. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
4. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation
5. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
6. Phase I and pharmacokinetic study of pemetrexed disodium (LY231514, MTA, Alimta) in patients (pts) with impaired renal function
7. A phase I and pharmacokinetic study of the multitargeted antifol (MTA) LY231514 with folic acid
8. Antitumor therapeutic index of LY309887 is improved with increased folic acid supplementation in mice maintained on a folate deficient diet
9. Relationship of metabolic profile, drug exposure, and other patient characteristics to toxicity
10. Phase I and pharmacokinetic study of the multitargeted antifol LY231514 (MTA) in combination with irinotecan (CPT-11)
11. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
12. Clinical and pharmacokinetic phase I study of MTA (multi-targeted antifolate, LY231514) and paclitaxel (P) in patients with solid tumors administered every 21 days
13. Phase I trial of pemetrexed (Alimta) and vinorelbine in patients (pts) with advanced cancer
14. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
15. MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin
16. A phase I study of the multitargeted antifolate ALIMTA in combination with oxaliplatin (LOHP) in metastatic solid tumors
17. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
18. A phase I study of the multitargeted antifolate LY231514 (MTA) in combination with 5-fluorouracil (5-FU): Schedule-dependent toxicity and tolerance
19. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro